Shorter six-month all-oral regimens for MDR/RR-TB are cost-effective and improve outcomes ICMR study shows Rs 379 less spent per patient per additional QALY with shorter regimens BPaL and BPaLM regimens are highly cost-effective versus longer bedaquiline-based treatments
